MetaCap

CDT Equity (CDT) vs Lisata Therapeutics (LSTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lisata Therapeutics is the larger company by market cap ($647,451 vs $437,033), about 1.5 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CDT-72.49%LSTA-23.17%
+64%-19%-103%
Oct 7, 20261 yearNov 20, 2026
CDT-67.97%LSTA-15.20%
+91%-4%-99%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CDT versus LSTA key metrics
MetricCDTLSTA
Share price$0.23$0.8989
Market cap$437.03K$647.45K
1-day change-13.89%-1.22%
YTD return—-51.67%
1-year return—-54.14%
5-year return—-93.89%
P/E ratio (TTM)0.00—
EPS (TTM)$1,816,250.00$-28.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$170.00K
Revenue growth (YoY)—-83.00%
Net income (latest FY)$-39.22M$-16.59M
Operating margin—-10711.18%
Net margin—-9756.47%
52-week high$291,250.00$76.05
52-week low$0.223$0.85
Distance from 52-week high-100.00%-98.82%
Analyst consensus—none
Average volume956.66K13.46K
Shares outstanding1.90M720.27K
Employees421
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About CDT Equity

CDT stock →

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Lisata Therapeutics

LSTA stock →

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

CDT vs LSTA FAQ

Which is bigger, CDT Equity or Lisata Therapeutics?

Lisata Therapeutics (LSTA) is larger, with a market capitalization of $647.45K compared with $437.03K for CDT Equity (CDT).

Are CDT Equity and Lisata Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons